Author Affiliations: Yale New Haven Health System Center for Outcomes Research and Evaluation (Dr Radford) and Section of Cardiovascular Medicine, Department of Medicine (Drs Radford and Foody), Yale University School of Medicine, New Haven, Conn; Qualidigm, Middletown, Conn (Drs Radford and Foody).
The impressive advances in cardiovascular therapy during the last several
decades owe a great deal to randomized trials.1
The foundation for 21st-century cardiovascular care has been laid, therapy
by therapy, through the disciplined application of randomized trial methodology
to important scientific insights and therapeutic uncertainties. The random
assignment of patients to receive one care strategy or therapy vs another
has allowed investigators to separate consistent therapeutic efficacy "signals"
from the "noise" of patient variability and physician bias.
Radford MJ, Foody JM. How Do Observational Studies Expand the Evidence Base for Therapy?. JAMA. 2001;286(10):1228-1230. doi:10.1001/jama.286.10.1228